Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28007154 | 0.80 | SMN1; SMN2 (0.39) | SMN1; SMN2KMT2AL3MBTL1MEN1 | |
| SCHEMBL6911384 | 0.77 | TYMP (0.44) | — | |
| SCHEMBL6512734 | 0.72 | — | — | |
| SCHEMBL887590 | 0.70 | DAO (0.38) | KMT2AL3MBTL1MEN1 | |
| SCHEMBL770542 | 0.68 | KMT2A (0.50) | KMT2A | |
| SCHEMBL12747285 | 0.66 | MET (0.35) | SMN1; SMN2KMT2AL3MBTL1MEN1 | |
| SCHEMBL4342113 | 0.66 | TYMP (0.49) | — | |
| SCHEMBL6510854 | 0.65 | DPYD (0.49) | SMN1; SMN2 | |
| SCHEMBL13350400 | 0.64 | MEN1 (0.32) | KMT2AMEN1 | |
| SCHEMBL20473363 | 0.63 | KDM4E (0.41) | SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059627-A1 | CRF2 ligands in combination therapy | HO SIEW PENG (US) | 2005-03-17 | — | — | US | claimed |
| EP-1383460-A2 | CRF 2? LIGANDS IN COMBINATION THERAPY | Bristol-Myers Squibb Pharma Company (US) | 2004-01-28 | — | — | EP | claimed |
| US-20020035083-A1 | CRF2 ligands in combination therapy | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-03-21 | — | — | US | claimed |
| WO-2002005749-A2 | CRF2 LIGANDS IN COMBINATION THERAPY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-24 | — | — | WO | claimed |
| US-20050059627-A1 | CRF2 ligands in combination therapy | HO SIEW PENG (US) | 2005-03-17 | — | — | US | disclosed |
| EP-1383460-A2 | CRF 2? LIGANDS IN COMBINATION THERAPY | Bristol-Myers Squibb Pharma Company (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20020035083-A1 | CRF2 ligands in combination therapy | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-03-21 | — | — | US | disclosed |
| WO-2002005749-A2 | CRF2 LIGANDS IN COMBINATION THERAPY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035083-A1 | CRF2 ligands in combination therapy | CRHR2, CRHR1, CRH | SMN1; SMN2 2565/4885KMT2A 3109/4885L3MBTL1 1174/4885 |
| US-20050059627-A1 | CRF2 ligands in combination therapy | CRHR2, CRHR1, CRH | SMN1; SMN2 2482/4885KMT2A 3163/4885L3MBTL1 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.